Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 0.71 below Ocugen Inc 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 119 other companies have achieved higher Quick Ratio than Ocugen Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 1654, from total ranking in the second quarter 2026 at 2725.

Explain Quick Ratio?
How much Cash & cash equivalents OCGN�s has?
What are OCGN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/OCGN/financial-strength

https://api.csimarket.com/api/v1/companies/OCGN/fundamentals

https://api.csimarket.com/api/v1/companies/OCGN/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

OCGN Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	483.96 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	158.73 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.71	Subscribe	Subscribe	Subscribe	Subscribe
OCGN's Total Ranking	# 1654	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-10.65 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-15.79 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 120
Healthcare Sector	# 690
Overall Market	# 2290

Quick Ratio Statistics
High	Average	Low
24.75	5.34	0.11
(Jun 30 2021)		(Jun 30 2019)

Financial Statements
Ocugen Inc 's Current Liabilities	$ 119 Millions	Visit OCGN's Balance sheet
Ocugen Inc 's Cash & cash equivalent	$ 84 Millions	Visit OCGN's Balance sheet
Source of OCGN's Sales		Visit OCGN's Sales by Geography

Cumulative Ocugen Inc 's Quick Ratio

OCGN's Quick Ratio for the trailling 12 Months

OCGN Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	284.95 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	50.57 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.79	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3968	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	49.97 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	28.24 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to OCGN Financial Strength Comparisons >> Go to Compare OCGN Quick Ratio to its Competitors

On the trailing twelve months basis Due to fall in Current Liabilities in the Q3 2026 to $118.90 millions, cumulative Quick Ratio decreased to 0.79 below the Ocugen Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Ocugen Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3092 to 3968.

Explain Quick Ratio?
How much Cash & cash equivalents OCGN�s has?
What are OCGN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 142
Healthcare Sector	# 896
Within the Market	# 3968

trailing twelve months Quick Ratio Statistics
High	Average	Low
16.23	4.23	0.3
(Dec 31 2021)		(Sep 30 2019)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Biocryst Pharmaceuticals Inc	1.92	$ 375.334 Millions	$ 195.830 Millions
Novavax inc	1.89	$ 622.363 Millions	$ 329.845 Millions
Elutia Inc	1.81	$ 29.093 Millions	$ 16.030 Millions
Lenz Therapeutics Inc	1.78	$ 31.610 Millions	$ 17.750 Millions
Acumen Pharmaceuticals Inc	1.74	$ 78.604 Millions	$ 45.087 Millions
Sana Biotechnology Inc	1.63	$ 121.728 Millions	$ 74.880 Millions
Aligos Therapeutics Inc	1.59	$ 31.094 Millions	$ 19.600 Millions
Atara Biotherapeutics Inc	1.51	$ 9.917 Millions	$ 6.568 Millions
Tarsus Pharmaceuticals Inc	1.36	$ 309.612 Millions	$ 227.114 Millions
Metagenomi Therapeutics Inc	1.12	$ 36.107 Millions	$ 32.340 Millions
Amgen Inc	1.11	$ 25,811.000 Millions	$ 23,231.000 Millions
Coherus Oncology inc	1.11	$ 83.629 Millions	$ 75.636 Millions
Sab Biotherapeutics Inc	0.98	$ 14.438 Millions	$ 14.798 Millions
Passage Bio Inc	0.97	$ 20.160 Millions	$ 20.743 Millions
Bio techne Corp	0.97	$ 350.036 Millions	$ 361.269 Millions
C4 Therapeutics Inc	0.81	$ 33.492 Millions	$ 41.460 Millions
Allogene Therapeutics Inc	0.76	$ 29.270 Millions	$ 38.498 Millions
Protalix Biotherapeutics inc	0.73	$ 22.035 Millions	$ 30.233 Millions
Ocugen Inc	0.71	$ 84.257 Millions	$ 118.901 Millions
Neurocrine Biosciences Inc	0.59	$ 739.100 Millions	$ 1,242.800 Millions
Iovance Biotherapeutics inc	0.55	$ 57.934 Millions	$ 105.774 Millions
Agenus Inc	0.43	$ 86.936 Millions	$ 203.691 Millions
Vaxcyte Inc	0.42	$ 125.470 Millions	$ 295.697 Millions
Vaxart Inc	0.41	$ 30.435 Millions	$ 73.934 Millions
Surrozen Inc	0.35	$ 100.353 Millions	$ 286.684 Millions
Biogen Inc	0.16	$ 628.100 Millions	$ 3,898.400 Millions

Date modified: 2026-11-05T06:30:16+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.